Covidh Technolog (534920)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROCE of 19.05%, if reliable, suggests some capital efficiency.
• Latest quarter net profit is ₹0 Cr, implying no significant cash burn at the moment.
• Small market cap of ₹22 Cr leaves theoretical room for a niche software/consulting business to scale, though no sales exist yet.

Concerns

• Zero revenue: latest quarter sales are ₹0 Cr and net profit is ₹0 Cr, so there is no demonstrated earning power.
• Extreme valuation: P/B of 1,879.64 against book value of ₹0.36 per share; P/E is meaningless at 0.00.
• Deterioration: profit growth -300%, ROE -19.11%, and Piotroski F-Score 3/9.
• Highly speculative price action: 52-week range ₹3.69 to ₹676.67, with no dividend or promoter holding data.

AI Analysis

Let me start with a simple rule: price is what you pay, value is what you get. Covidh Technolog has a price of ₹676.67 but the fundamental numbers show no value in the traditional sense. Latest quarter sales are ₹0 crore, net profit is ₹0 crore, and profit growth is -300%. With no earnings, the P/E of 0.00 is meaningless. Book value is a thin ₹0.36 per share, so the market cap of ₹22 crore rests on a price-to-book of 1,879.64. That is not valuation; that is speculation. The reported ROCE of 19.05% catches the eye, but I cannot build a narrative on it when the company has zero revenue. ROE is -19.11%, and the Piotroski F-Score is only 3 out of 9, signalling weak financial health. The FairStock score is N/A due to insufficient data, which is an honest warning. The 52-week range from ₹3.69 to ₹676.67 is a loud warning: this stock has moved more like a lottery ticket than a business. There is no dividend yield, promoter holding is not available, and debt/equity is not available. Graham taught me to invest only when you can estimate intrinsic value with a margin of safety. Here, I cannot estimate intrinsic value because there is no underlying earning power. The market is pricing a perfect turnaround, but the data gives no evidence of one. A small market cap does not make a good investment; a good business makes a good investment. I would put Covidh Technolog in the 'too hard' pile and watch for actual revenue, profits, and a reasonable price-to-book before reconsidering.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer